ArticleAnnals of translational medicine2020

The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center.

Qianqian Long et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.